Amal Y Al-Yasiri1,2, Nathan E White1, Kattesh V Katti1,3,4,5,6, Sudarshan K Loyalka1,7. 1. Nuclear Science and Engineering Institute, University of Missouri, Columbia, MO, USA. 2. Department of Basic Sciences, College of Dentistry, University of Baghdad, Bab Al-Muadham, Baghdad, Iraq. 3. Cancer Nanotechnology Platform, University of Missouri, Columbia, MO, USA. 4. Institute of Green Nanotechnology, University of Missouri, Columbia, MO, USA. 5. Department of Physics and Astronomy, University of Missouri, Columbia, MO, USA. 6. Department of Radiology, University of Missouri, Columbia, MO, USA. 7. Particulate Systems Research Center, University of Missouri, Columbia, MO, USA.
Abstract
AIM: The objective of this research was to estimate the dose distribution delivered by radioactive gold nanoparticles (198AuNPs or 199AuNPs) to the tumor inside the human prostate as well as to normal tissues surrounding the tumor using the Monte-Carlo N-Particle code (MCNP-6.1.1 code). BACKGROUND: Radioactive gold nanoparticles are emerging as promising agents for cancer therapy and are being investigated to treat prostate cancer in animals. In order to use them as a new therapeutic modality to treat human prostate cancer, accurate radiation dosimetry simulations are required to estimate the energy deposition in the tumor and surrounding tissue and to establish the course of therapy for the patient. MATERIALS AND METHODS: A simple geometrical model of a human prostate was used, and the dose deposited by 198AuNPs or 199AuNPs to the tumor within the prostate as well as to the healthy tissue surrounding the prostate was calculated using the MCNP code. Water and A-150 TEP phantoms were used to simulate the soft and tumor tissues. RESULTS: The results showed that the dose due to 198AuNPs or 199AuNPs, which are distributed homogenously in the tumor, had a maximal value in the tumor region and then rapidly decreased toward the prostate-tumor interface and surrounding organs. However, the dose deposited by 198Au is significantly higher than the dose deposited by 199Au in the tumor region as well as normal tissues. CONCLUSIONS: According to the MCNP results, 198AuNPs are a promising modality to treat prostate cancer and other cancers and 199AuNPs could be used for imaging purposes.
AIM: The objective of this research was to estimate the dose distribution delivered by radioactive gold nanoparticles (198AuNPs or 199AuNPs) to the tumor inside the human prostate as well as to normal tissues surrounding the tumor using the Monte-Carlo N-Particle code (MCNP-6.1.1 code). BACKGROUND: Radioactive gold nanoparticles are emerging as promising agents for cancer therapy and are being investigated to treat prostate cancer in animals. In order to use them as a new therapeutic modality to treat human prostate cancer, accurate radiation dosimetry simulations are required to estimate the energy deposition in the tumor and surrounding tissue and to establish the course of therapy for the patient. MATERIALS AND METHODS: A simple geometrical model of a human prostate was used, and the dose deposited by 198AuNPs or 199AuNPs to the tumor within the prostate as well as to the healthy tissue surrounding the prostate was calculated using the MCNP code. Water and A-150 TEP phantoms were used to simulate the soft and tumor tissues. RESULTS: The results showed that the dose due to 198AuNPs or 199AuNPs, which are distributed homogenously in the tumor, had a maximal value in the tumor region and then rapidly decreased toward the prostate-tumor interface and surrounding organs. However, the dose deposited by 198Au is significantly higher than the dose deposited by 199Au in the tumor region as well as normal tissues. CONCLUSIONS: According to the MCNP results, 198AuNPs are a promising modality to treat prostate cancer and other cancers and 199AuNPs could be used for imaging purposes.
Authors: V Bouchat; V E Nuttens; S Lucas; C Michiels; B Masereel; O Féron; B Gallez; T Vander Borght Journal: Med Phys Date: 2007-11 Impact factor: 4.071
Authors: Amir R Jalilian; Blanca Ocampo-García; Wanvimol Pasanphan; Tamer M Sakr; Laura Melendez-Alafort; Mariano Grasselli; Ademar B Lugao; Hassan Yousefnia; Clelia Dispenza; Siti Mohd Janib; Irfan U Khan; Michał Maurin; Piotr Ulański; Say Chye Joachim Loo; Agnes Safrany; Joao A Osso; Adriano Duatti; Kattesh V Katti Journal: Pharmaceutics Date: 2022-05-15 Impact factor: 6.525
Authors: Baljeet Seniwal; Velaphi C Thipe; Sukhvir Singh; Telma C F Fonseca; Lucas Freitas de Freitas Journal: Front Oncol Date: 2021-11-24 Impact factor: 6.244